{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:19:12Z","timestamp":1795108752369,"version":"4.10.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but frequently cause immune-related adverse events (IrAEs). ICI-induced large vessel vasculitis (LVV) is a rare IrAE, with limited available data. We aimed to describe and compare clinical characteristics and evolution of ICI-induced LVV to primary LVV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, multicentre European study included adult patients who developed LVV after ICI therapy between March 2018 and August 2024. Patients were compared with matched controls with primary LVV. LVV was defined histologically and\/or morphologically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven patients were included [median (interquartile range) age 68 (61\u201374) years]. Five (19%) had a history of polymyalgia rheumatica or GCA. Median time from ICIs initiation to LVV diagnosis was 3 (2\u201317) months. Eight patients (30%) received ipilimumab\u2013nivolumab combination therapy, all of whom developed LVV within 6\u2009months. Most clinical features were similar to matched controls, however PET scan diagnosis and large-vessel involvement were more common in ICI-induced LVV. Visual loss occurred in 4 (15%) patients. Management included discontinuation of ICIs in 19 (70%) patients and administration of glucocorticoids. After a median follow-up of 12 (5\u201320) months, 20 (74%) achieved sustained remission. Relapse or treatment failure of LVV occurred in 3\/9 (33%) patients who continued ICIs and 4\/18 (22%) who discontinued them. By last follow-up, 9 (33%) patients had died, mainly from cancer (n\u2009=\u20098).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICI-induced LVV is a rare, early-onset IrAE. Although continuation of ICIs may affect LVV outcomes, cancer progression remains the primary cause of mortality. Prospective studies are warranted to better balance therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf172","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T18:42:37Z","timestamp":1743273757000},"page":"4546-4554","source":"Crossref","is-referenced-by-count":11,"title":["Immune checkpoint inhibitors\u2013induced large vessel vasculitis: clinical characteristics and management from a European multicentre study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-2949","authenticated-orcid":false,"given":"Adrien","family":"Cottu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Delaval","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint-Denis Hospital , Saint-Denis,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Forestier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Oscar Lambret , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-2078","authenticated-orcid":false,"given":"Alessandro","family":"Tomelleri","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Disease, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-3794","authenticated-orcid":false,"given":"Corrado","family":"Campochiaro","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Disease, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-2955","authenticated-orcid":false,"given":"Milena","family":"Bond","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University , Brunico,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-0351","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Dion","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Toulouse University Hospital Oncopole , Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Gury","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Arras GHAT , Arras,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Savary","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Brest CHU Hospital , Brest,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Dhote","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Avicenne , Bobigny,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-5001","authenticated-orcid":false,"given":"Albrecht","family":"Betrains","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, University Hospitals Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[{"name":"Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC , Grenoble,","place":["France"]},{"name":"Internal Medicine Department, Grenoble University Hospital , Grenoble,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Liozon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Limoges , Limoges Cedex,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Bories","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Purpan CHU Hospital , Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Petitdemange","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Legendre","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Centre hospitalier du Mans , Le Mans,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Crichi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Kerschen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Luxembourg Hospital Center , Luxembourg City,","place":["Luxembourg"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Carneiro Esteves","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire de Saint-Etienne , Saint-Etienne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Armengol","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Clinique Saint-Hilaire , Rouen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderau","family":"Outh","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Perpignan Hospital Center , Perpignan,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Al Tabaa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital NOVO , Pontoise,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pitaux Universitaires de Bruxelles, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Ilzkovitz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pitaux Universitaires de Bruxelles, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Yassine","family":"Cherif","sequence":"additional","affiliation":[{"name":"Department of Rhumatology, H\u00f4pitaux Universitaires de Bruxelles, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department for the Organization of Patient Pathways\u2014DIOPP, Gustave Roussy , Villejuif,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Disease, IRCCS San Raffaele Hospital , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2350-2914","authenticated-orcid":false,"given":"Patrick","family":"Bruneval","sequence":"additional","affiliation":[{"name":"Department of Pathology, Georges-Pompidou European Hospital, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-7336","authenticated-orcid":false,"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris (AP-HP) , Paris,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025080115373934200_keaf172-B1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2025080115373934200_keaf172-B2","doi-asserted-by":"crossref","first-page":"e14613","DOI":"10.1200\/JCO.2024.42.16_suppl.e14613","article-title":"Updated estimates of eligibility and response: immune checkpoint inhibitors","volume":"42","author":"Prasad","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025080115373934200_keaf172-B3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primer"},{"key":"2025080115373934200_keaf172-B4","doi-asserted-by":"crossref","first-page":"152440","DOI":"10.1016\/j.semarthrit.2024.152440","article-title":"A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: unraveling the complexities at the intersection of immunology and vascular pathology","volume":"66","author":"Lee","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025080115373934200_keaf172-B5","first-page":"keae711","article-title":"Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course","author":"Chanson","year":"2024","journal-title":"Rheumatology"},{"key":"2025080115373934200_keaf172-B6","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2025080115373934200_keaf172-B7","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1093\/annonc\/mdx306","article-title":"An unknown reaction to pembrolizumab: giant cell arteritis","volume":"28","author":"Micaily","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2025080115373934200_keaf172-B8","doi-asserted-by":"crossref","first-page":"100891","DOI":"10.1016\/j.ajoc.2020.100891","article-title":"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma","volume":"20","author":"Narala","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2025080115373934200_keaf172-B9","first-page":"S555","article-title":"Immune checkpoint inhibitor-associated polymyalgia rheumatica\/giant cell arteritis occurring in a patient after treatment with nivolumab","volume":"27","author":"Betrains","year":"2021","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"2025080115373934200_keaf172-B10","doi-asserted-by":"crossref","first-page":"e246443","DOI":"10.1136\/bcr-2021-246443","article-title":"Giant cell arteritis associated with PD-1 inhibition","volume":"14","author":"Couette","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025080115373934200_keaf172-B11","first-page":"e50121","article-title":"A rare case of giant cell arteritis after the administration of checkpoint inhibitor therapy in a metastatic renal cell carcinoma patient","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"2025080115373934200_keaf172-B12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCRESAHA.122.322330","article-title":"CTLA-4 pathway is instrumental in giant cell arteritis","volume":"133","author":"R\u00e9gnier","year":"2023","journal-title":"Circ Res"},{"key":"2025080115373934200_keaf172-B13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025080115373934200_keaf172-B14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/rheumatology\/kead471","article-title":"Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review","volume":"63","author":"Hysa","year":"2024","journal-title":"Rheumatology"},{"key":"2025080115373934200_keaf172-B15","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3390\/jcm11102905","article-title":"New insights into the pathogenesis of giant cell arteritis: mechanisms involved in maintaining vascular inflammation","volume":"11","author":"Greigert","year":"2022","journal-title":"J Clin Med"},{"key":"2025080115373934200_keaf172-B16","first-page":"E970","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025080115373934200_keaf172-B17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2025080115373934200_keaf172-B18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025080115373934200_keaf172-B19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard-2022-223429","article-title":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","volume":"83","author":"Dejaco","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025080115373934200_keaf172-B20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2025080115373934200_keaf172-B21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2025080115373934200_keaf172-B22","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025080115373934200_keaf172-B23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.autrev.2019.05.008","article-title":"Large-vessel vasculitis diagnosed between 50 and 60\u202fyears: case-control study based on 183 cases and 183 controls aged over 60\u202fyears","volume":"18","author":"Delaval","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025080115373934200_keaf172-B24","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025080115373934200_keaf172-B25","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/ard-2023-223895","article-title":"Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients","volume":"82","author":"Monti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025080115373934200_keaf172-B26","first-page":"ard-2024-225515","article-title":"Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis","author":"Chaddock","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 117","key":"2025080115373934200_keaf172-B27","first-page":"57","article-title":"The different clinical patterns of giant cell arteritis","volume":"37","author":"de Boysson","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025080115373934200_keaf172-B28","first-page":"39","article-title":"The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"2025080115373934200_keaf172-B29","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025080115373934200_keaf172-B30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025080115373934200_keaf172-B31","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025080115373934200_keaf172-B32","first-page":"335","article-title":"Clinical characteristics and follow-up of 60 patients with recent diagnosis of giant cell arteritis, NEWTON study","volume":"45","author":"Lomba Goncalves","year":"2024","journal-title":"Rev Med Interne"},{"key":"2025080115373934200_keaf172-B33","first-page":"keae099","article-title":"Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement","author":"Vermeulen","year":"2024","journal-title":"Rheumatology"},{"key":"2025080115373934200_keaf172-B34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2025080115373934200_keaf172-B35","doi-asserted-by":"crossref","first-page":"e006814","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa\u2019ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025080115373934200_keaf172-B36","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1136\/annrheumdis-2020-217225","article-title":"Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy","volume":"81","author":"Martin de Fremont","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf172\/62748413\/keaf172.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4546\/62748413\/keaf172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4546\/62748413\/keaf172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T19:37:48Z","timestamp":1754077068000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/8\/4546\/8096385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,3,26]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf172","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,3,26]]}}}